Catalpol Attenuates Hepatic Steatosis by Regulating Lipid Metabolism via AMP-Activated Protein Kinase Activation

Figure 5

Catalpol treatment prevented hepatic steatosis in high-fat diet- (HFD-) fed mice. (a) Hematoxylin and eosin staining of the hepatic sections (200x): (i) normal, (ii) HFD, (iii) HFD+catalpol (100 mg/kg, oral gavage), (iv) HFD+catalpol (200 mg/kg, oral gavage), (v) HFD+catalpol (400 mg/kg, oral gavage), and (vi) HFD+atorvastatin calcium (ATC, 30 mg/kg, oral gavage). (b) Oil Red O staining of the hepatic sections (200x): (i) normal, (ii) HFD, (iii) HFD+catalpol (100 mg/kg, oral gavage), (iv) HFD+catalpol (200 mg/kg, oral gavage), (v) HFD+catalpol (400 mg/kg, oral gavage), and (vi) HFD+ATC (30 mg/kg, oral gavage). (c) Percentage area of hepatic tissue occupied by lipid droplets. (d) Liver index. Data are presented as the (). vs. the Normal group; ^#, ^## vs. the HFD group.

(a)

(b)

(c)

(d)